Live
FierceBiotechInsulet recalls certain Omnipod 5 pumps over insulin leak risksEndpoints NewsRoivant CEO, bullish on internal growth, dodges M&A chatterBioWorldIn the clinic for Oct. 28, 2025BioWorldIn the clinic for March 6, 2026BioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-March 13, 2026BioPharma DiveWith FDA go ahead, a China biotech notches a first in cell therapy testingFierceBiotechInovio trims team as trouble brews at FDA for rare disease candidateFierceBiotechSana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patientFierceBiotechChina approves first brain-computer interface implant for paralyzed patients, as sector heats upBioWorldFDA ‘blacklist’ in DMD? Legislator slams PTC turndownBioPharma DiveGSK’s RSV vaccine wins broader FDA clearance
Endpoints News Mar 13, 2026

Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease

Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease

Original
Body unavailable. Use the original source.

Directory

59 All